Antibody-drug conjugates, a well-established antitumor strategy, are used for targeted delivery of cytotoxic drugs through antibodies. As cancer research progresses, other technologies with different mechanisms are advancing in the oncologic pipeline. Researchers from Cybrexa Therapeutics Inc. presented new preclinical data on CBX-15, a peptide-drug conjugate (PDC) consisting of a pH-low insertion peptide (pHLIP) linked to monomethyl auristatin E (MMAE).
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full day of the conference, reports from the first HIV cure trial conducted in Africa, the RIO trial and others showed that perhaps, a broadly useful cure is on the horizon.
University of Antwerp has described fibroblast activation protein (FAP) inhibitors reported to be useful for the diagnosis and treatment of cancer, disorders of coagulation, glucose metabolism and inflammatory disorders.
Biotheryx Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a son of sevenless homolog 1 (SOS1) targeting moiety reported to be useful for the treatment of cancer.
Bisichem Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, asthma, stroke, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, among others.
Mindrank Ltd. has announced that the FDA has cleared the company’s IND application for MRANK-106, a potentially first-in-class, orally available dual inhibitor of WEE1 and YES1 kinases, for the treatment of pancreatic cancer, small-cell lung cancer, ovarian cancer, breast cancer and colorectal cancer.
Eosinophilic otitis media (EOM) is a type 2-related otitis media. Scientists at the Hirosaki University Graduate School of Medicine have developed a new EOM animal model in guinea pigs by using the plant protease papain. Papin was intratympanically administered in a daily basis. They also investigated the expression of innate lymphoid cell type 2 (ILC2) in the middle ear mucosa of these animals.
Neurodevelopmental disorders related to protein phosphatase 2A (PP2A) have been recently renamed as Houge-Janssens syndrome and they are caused by heterozygous, de novo pathogenic genetic variants in the PPP2R5D, PPP2R1A or PPP2CA genes. The syndrome is characterized by features such as intellectual disability, autism, developmental delay, seizures or brain abnormalities, among others.
RSS
